Peregrine Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-832
| Closed | -$379K | – | 296 |
|
|
2025
Q3 | $379K | Sell |
832
-315
| -27% | -$128K | 0.01% | 279 |
|
|
2025
Q2 | $374K | Hold |
1,147
| – | – | 0.01% | 277 |
|
|
2025
Q1 | $310K | Hold |
1,147
| – | – | 0.01% | 279 |
|
|
2024
Q4 | $270K | Hold |
1,147
| – | – | 0.01% | 282 |
|
|
2024
Q3 | $315K | Hold |
1,147
| – | – | 0.01% | 280 |
|
|
2024
Q2 | $279K | Hold |
1,147
| – | – | 0.01% | 284 |
|
|
2024
Q1 | $171K | Hold |
1,147
| – | – | ﹤0.01% | 282 |
|
|
2023
Q4 | $220K | Hold |
1,147
| – | – | 0.01% | 280 |
|
|
2023
Q3 | $203K | Hold |
1,147
| – | – | 0.01% | 282 |
|
|
2023
Q2 | $218K | Hold |
1,147
| – | – | 0.01% | 286 |
|
|
2023
Q1 | $230K | Hold |
1,147
| – | – | 0.01% | 281 |
|
|
2022
Q4 | $273K | Hold |
1,147
| – | – | 0.01% | 277 |
|
|
2022
Q3 | $230K | Sell |
1,147
-233
| -17% | -$44.4K | 0.01% | 282 |
|
|
2022
Q2 | $201K | Hold |
1,380
| – | – | 0.01% | 286 |
|
|
2022
Q1 | $225K | Hold |
1,380
| – | – | 0.01% | 289 |
|
|
2021
Q4 | $234K | Hold |
1,380
| – | – | ﹤0.01% | 292 |
|
|
2021
Q3 | $261K | Hold |
1,380
| – | – | 0.01% | 289 |
|
|
2021
Q2 | $234K | Hold |
1,380
| – | – | ﹤0.01% | 290 |
|
|
2021
Q1 | $195K | Hold |
1,380
| – | – | ﹤0.01% | 293 |
|
|
2020
Q4 | $179K | Hold |
1,380
| – | – | ﹤0.01% | 289 |
|
|
2020
Q3 | $201K | Sell |
1,380
-93,386
| -99% | -$13.3M | 0.01% | 301 |
|
|
2020
Q2 | $14M | Sell |
94,766
-13,909
| -13% | -$1.88M | 0.4% | 103 |
|
|
2020
Q1 | $11.8M | Sell |
108,675
-43,962
| -29% | -$5.07M | 0.42% | 96 |
|
|
2019
Q4 | $17.6M | Sell |
152,637
-38,648
| -20% | -$3.85M | 0.45% | 96 |
|
|
2019
Q3 | $15.4M | Sell |
191,285
-39,757
| -17% | -$3.15M | 0.42% | 107 |
|
|
2019
Q2 | $16.8M | Buy |
231,042
+37,821
| +20% | +$2.9M | 0.41% | 103 |
|
|
2019
Q1 | $18.1M | Sell |
193,221
-3,580
| -2% | -$299K | 0.45% | 95 |
|
|
2018
Q4 | $14.3M | Sell |
196,801
-1,237
| -0.6% | -$95.1K | 0.4% | 109 |
|
|
2018
Q3 | $17.3M | Buy |
198,038
+19,433
| +11% | +$1.95M | 0.41% | 112 |
|
|
2018
Q2 | $17.6M | Buy |
178,605
+36,886
| +26% | +$3.66M | 0.44% | 98 |
|
|
2018
Q1 | $16.9M | Sell |
141,719
-6,680
| -5% | -$861K | 0.41% | 96 |
|
|
2017
Q4 | $18.9M | Sell |
148,399
-16,465
| -10% | -$2.07M | 0.44% | 86 |
|
|
2017
Q3 | $19.4M | Sell |
164,864
-34,224
| -17% | -$2.92M | 0.46% | 79 |
|
|
2017
Q2 | $15.9M | Sell |
199,088
-22,821
| -10% | -$1.46M | 0.4% | 97 |
|
|
2017
Q1 | $11.7M | Buy |
221,909
+15,477
| +7% | +$715K | 0.3% | 130 |
|
|
2016
Q4 | $7.73M | Buy |
206,432
+22,033
| +12% | +$923K | 0.2% | 227 |
|
|
2016
Q3 | $12.5M | Buy |
+184,399
| New | +$13M | 0.33% | 128 |
|
Other funds holding ALNY
Peregrine Capital Management's ALNY Position: Q4 2025 in Review
Peregrine Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 832 shares — an estimated $379K sold.
Peregrine Capital Management first reported a position in ALNY in Q3 2016 and held it in 37 quarters. The position peaked at $19.4M in Q3 2017. 848 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.
- Peregrine Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Peregrine Capital Management sold 832 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $379K.
- Peregrine Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2016 and held it in 37 quarters.
- Peregrine Capital Management's Alnylam Pharmaceuticals position peaked at $19.4M in Q3 2017.
- 848 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.
Based on Peregrine Capital Management's 13F filing for Q4 2025, filed 28 Jan 2026.